|Articles|September 15, 2016

Bracket Randomizes First Patient Using PBD Tech

Bracket has randomized its first patient using Precision Block Design (PBD) technology fully integrated into its clinical IRT platform and its mobile application.

Bracket has randomized its first patient using Precision Block Design (PBD) technology fully integrated into its clinical IRT platform and its mobile application. This technology was created for sponsors who want or need to utilize block pattern distribution in their randomization lists.

Read the full release here

Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.

Related to this article

November 12th, 2026

Why So Many Patients From Underrepresented Groups Are Never Asked to Join a Trial

In this video interview, Shaalan Beg, MD, MBA, FASCO, chief medical officer at ConcertAI, explains why trial availability, shaped heavily by zip code, is the biggest barrier to enrollment and how access patterns mirror broader healthcare disparities.

November 12th, 2026

Why APAC Clinical Trial Sites Deserve a Second Look: Q&A with James Cheong, Precision for Medicine

In this Q&A, James Cheong, senior vice president of Asia Pacific at Precision for Medicine, discusses why outdated perceptions of APAC sites persist among smaller biotechs, how China’s regulatory reforms have reshaped Phase III startup timelines, and what first-time sponsors need to get right in the region.

November 12th, 2026

ACT Brief: APAC Sponsor Priorities, Continuous Glucose Monitoring Trials, and GLP-1 Eye Warning

In today’s ACT Brief, we examine three priorities for first-time APAC sponsors, how continuous glucose monitoring should be used in diabetes trials, and why FDA is requiring a new eye-related warning across GLP-1 medications.

November 11th, 2026

What Smaller Biotechs Need to Get Right in Their First APAC Phase III Trial

In this video interview, James Cheong, senior vice president of Asia Pacific at Precision for Medicine, shares three priorities for first-time APAC sponsors: aligning with marketing authorization plans, selecting the right sites, and choosing a CRO with regional experience and KOL networks.

How regulatory guidance, blinding, study-provisioned devices, and ePRO integration shape reliable CGM data collection in diabetes clinical trials. Credit: Stock.Adobe.com/martenaba

November 11th, 2026

Continuous Glucose Monitoring in Diabetes Clinical Trials: Endpoints, Regulatory Guidance, and Operational Best Practices

FDA and EMA expectations shape how sponsors use CGM in diabetes trials, from blinding and study-provisioned devices to data integrity and ePRO integration.

November 11th, 2026

ACT Brief: APAC Trial Advantages, Learning From Setbacks, and Sunharbo Stroke Prevention Approval

In today’s ACT Brief, we examine why APAC is attractive for global Phase III programs, how clinical research professionals can turn a failed pivotal trial into a redesigned success, and how FDA approved Sunharbo to reduce recurrent stroke risk.

November 10th, 2026

The Role of Clinical Research Professionals: From Early Discovery to Phase III Success

A pivotal trial that missed its primary endpoint became the basis for a successful redesign after the team used the data to define the high-risk patients most likely to benefit, showing that setbacks can strengthen development when organizations interrogate the evidence rather than abandon it.

November 10th, 2026

What Large Pharma Has Figured Out About APAC That Smaller Biotechs Are Still Learning

In this video interview, James Cheong, senior vice president of Asia Pacific at Precision for Medicine, outlines why faster recruitment, local data requirements for registration, and lower costs make APAC attractive for global Phase III programs.

Bracket Randomizes First Patient Using PBD Tech

Related to this article

Trending on Applied Clinical Trials Online

Continuous Glucose Monitoring in Diabetes Clinical Trials: Endpoints, Regulatory Guidance, and Operational Best Practices

What Smaller Biotechs Need to Get Right in Their First APAC Phase III Trial

The Role of Clinical Research Professionals: From Early Discovery to Phase III Success

ACT Brief: APAC Trial Advantages, Learning From Setbacks, and Sunharbo Stroke Prevention Approval

Why So Many Patients From Underrepresented Groups Are Never Asked to Join a Trial